Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-084321
Filing Date
2025-04-17
Accepted
2025-04-17 16:08:26
Documents
8

Document Format Files

Seq Description Document Type Size
1 DEFA14A d878690ddefa14a.htm DEFA14A 21796
2 GRAPHIC g878690dsp2b.jpg GRAPHIC 29547
3 GRAPHIC g878690dsp2c.jpg GRAPHIC 63040
4 GRAPHIC g878690dsp2d.jpg GRAPHIC 4199
5 GRAPHIC g878690dsp2e.jpg GRAPHIC 3403
6 GRAPHIC g878690dsp2f.jpg GRAPHIC 4116
7 GRAPHIC g878690dsp2g.jpg GRAPHIC 5881
8 GRAPHIC g878690dsp3a.jpg GRAPHIC 11313
  Complete submission text file 0001193125-25-084321.txt   191198
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40656 | Film No.: 25847359
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)